Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2019, Article ID 2024648, 14 pages
https://doi.org/10.1155/2019/2024648
Research Article

Dovitinib Triggers Apoptosis and Autophagic Cell Death by Targeting SHP-1/p-STAT3 Signaling in Human Breast Cancers

1Department of Nursing, St. Mary’s Junior College of Medicine, Nursing and Management, Yilan 26647, Taiwan
2Institute of Long-Term Care, Mackay Medical College, New Taipei City 25245, Taiwan
3Department of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, 1 Sec 4 Roosevelt Road, Taipei 10617, Taiwan
4Holistic Education Center, Mackay Medical College, New Taipei City 25245, Taiwan
5Animal Cancer Center, College of Bioresources and Agriculture, National Taiwan University, 1 Sec 4 Roosevelt Road, Taipei 10617, Taiwan

Correspondence should be addressed to Chen-Si Lin; wt.ude.utn@001nilsc

Received 29 June 2019; Accepted 29 July 2019; Published 14 August 2019

Guest Editor: Chia-Jung Li

Copyright © 2019 Yi-Han Chiu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. E. DeSantis, J. Ma, A. Goding Sauer, L. A. Newman, and A. Jemal, “Breast cancer statistics, 2017, racial disparity in mortality by state,” CA: A Cancer Journal for Clinicians, vol. 67, no. 6, pp. 439–448, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Pathmanathan, J.-S. Geng, W. Li et al., “Human epidermal growth factor receptor 2 status of breast cancer patients in Asia: results from a large, multicountry study,” Asia-Pacific Journal of Clinical Oncology, vol. 12, no. 4, pp. 369–379, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Masuda, D. Zhang, C. Bartholomeusz, H. Doihara, G. N. Hortobagyi, and N. T. Ueno, “Role of epidermal growth factor receptor in breast cancer,” Breast Cancer Research and Treatment, vol. 136, no. 2, pp. 331–345, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. C. M. Connell and G. J. Doherty, “Activating HER2 mutations as emerging targets in multiple solid cancers,” ESMO Open, vol. 2, no. 5, Article ID e000279, 2017. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Ercan, K. Zejnullahu, K. Yonesaka et al., “Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor,” Oncogene, vol. 29, no. 16, pp. 2346–2356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. I. F. Tannock, C. M. Lee, J. K. Tunggal, D. S. M. Cowan, and M. J. Egorin, “Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy,” Clinical Cancer Research, vol. 8, no. 3, pp. 878–884, 2002. View at Google Scholar
  7. M. Katoh, “FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (review),” International Journal of Molecular Medicine, vol. 38, no. 1, pp. 3–15, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Perez-Garcia, E. Muñoz-Couselo, J. Soberino, F. Racca, and J. Cortes, “Targeting FGFR pathway in breast cancer,” The Breast, vol. 37, pp. 126–133, 2018. View at Publisher · View at Google Scholar · View at Scopus
  9. M. T. Herrera-Abreu, A. Pearson, J. Campbell et al., “Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer,” Cancer Discovery, vol. 3, no. 9, pp. 1058–1071, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. S. A. Kono, M. E. Marshall, K. E. Ware, and L. E. Heasley, “The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer,” Drug Resistance Updates, vol. 12, no. 4-5, pp. 95–102, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. H. Lee, D. Lopes de Menezes, J. Vora et al., “In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models,” Clinical Cancer Research, vol. 11, no. 10, pp. 3633–3641, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Porta, P. Giglione, W. Liguigli, and C. Paglino, “Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity,” Future Oncology, vol. 11, no. 1, pp. 39–50, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. D. E. Lopes de Menezes, J. Peng, E. N. Garrett et al., “CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia,” Clinical Cancer Research, vol. 11, no. 14, pp. 5281–5291, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Guo, P. A. Marcotte, J. O. McCall et al., “Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors,” Molecular Cancer Therapeutics, vol. 5, no. 4, pp. 1007–1013, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. P. A. Renhowe, S. Pecchi, C. M. Shafer et al., “Design, structure−activity relationships and in vivo characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors,” Journal of Medicinal Chemistry, vol. 52, no. 2, pp. 278–292, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. G. E. Konecny, T. Kolarova, N. A. O’Brien et al., “Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells,” Molecular Cancer Therapeutics, vol. 12, no. 5, pp. 632–642, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Andre, T. Bachelot, M. Campone et al., “Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer,” Clinical Cancer Research, vol. 19, no. 13, pp. 3693–3702, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. K. B. Kim, J. Chesney, D. Robinson, H. Gardner, M. M. Shi, and J. M. Kirkwood, “Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma,” Clinical Cancer Research, vol. 17, no. 23, pp. 7451–7461, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. H. J. Chon, Y. Lee, K. J. Bae, B. J. Byun, S. A. Kim, and J. Kim, “Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells,” Amino Acids, vol. 48, no. 7, pp. 1591–1599, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Zang, J. Eucker, P. Habbel et al., “Targeting multiple tyrosine kinase receptors with Dovitinib blocks invasion and the interaction between tumor cells and cancer-associated fibroblasts in breast cancer,” Cell Cycle, vol. 14, no. 8, pp. 1291–1299, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Chase, F. H. Grand, and N. C. P. Cross, “Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome,” Blood, vol. 110, no. 10, pp. 3729–3734, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. W.-T. Tai, A.-L. Cheng, C.-W. Shiau et al., “Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3,” Molecular Cancer Therapeutics, vol. 11, no. 2, pp. 452–463, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Z. P. Chai, M. K. Shanmugam, F. Arfuso et al., “Targeting transcription factor STAT3 for cancer prevention and therapy,” Pharmacology & Therapeutics, vol. 162, pp. 86–97, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. Zhang, K. Shen, W. Lu, and P. A. Cole, “The role of C-terminal tyrosine phosphorylation in the regulation of SHP-1 explored via expressed protein ligation,” Journal of Biological Chemistry, vol. 278, no. 7, pp. 4668–4674, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. T. T. Huang, J. C. Su, C. Y. Liu, C. W. Shiau, and K. F. Chen, “Alteration of SHP-1/p-STAT3 signaling: a potential target for anticancer therapy,” International Journal of Molecular Sciences, vol. 18, no. 6, p. E1234, 2017. View at Publisher · View at Google Scholar · View at Scopus
  26. C. W. Elston and I. O. Ellis, “Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up,” Histopathology, vol. 19, no. 5, pp. 403–410, 1991. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Elliott and J. J. Reiners, “Suppression of autophagy enhances the cytotoxicity of the DNA-damaging aromatic amine p-anilinoaniline,” Toxicology and Applied Pharmacology, vol. 232, no. 2, pp. 169–179, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Yu, Y. Chen, and S. A. Tooze, “Autophagy pathway: cellular and molecular mechanisms,” Autophagy, vol. 14, no. 2, pp. 207–215, 2018. View at Publisher · View at Google Scholar · View at Scopus
  29. M. C. Maiuri, G. Le Toumelin, A. Criollo et al., “Functional and physical interaction between Bcl-XL and a BH3-like domain in Beclin-1,” The EMBO Journal, vol. 26, no. 10, pp. 2527–2539, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. J. J. Shacka, B. J. Klocke, and K. A. Roth, “Autophagy, bafilomycin and cell death: the “A-B-Cs” of plecomacrolide-induced neuroprotection,” Autophagy, vol. 2, no. 3, pp. 228–230, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Gaur, L. Chen, V. Ann et al., “Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status,” Molecular Cancer, vol. 13, no. 1, p. 21, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Issa, J. W. Gill, M. R. Heideman et al., “Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models,” Breast Cancer Research, vol. 15, no. 1, p. R8, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. H. Chiu, S. H. Hsu, H. W. Hsu et al., “Human non-small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy,” International Journal of Oncology, vol. 53, no. 5, pp. 1967–1979, 2018. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Lopez-Ruiz, J. Rodriguez-Ubreva, A. Ernesto Cariaga, M. Alicia Cortes, and B. Colas, “SHP-1 in cell-cycle regulation,” Anti-Cancer Agents in Medicinal Chemistry, vol. 11, no. 1, pp. 89–98, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Witkiewicz, P. Raghunath, A. Wasik et al., “Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma,” Human Pathology, vol. 38, no. 3, pp. 462–467, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. W.-T. Tai, C.-W. Shiau, H.-L. Chen et al., “Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells,” Cell Death & Disease, vol. 4, no. 2, p. e485, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Bhattacharya, R. M. Ray, and L. R. Johnson, “STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells,” Biochemical Journal, vol. 392, no. 2, pp. 335–344, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. A. H. Boulares, A. G. Yakovlev, V. Ivanova et al., “Role of poly (ADP-ribose) polymerase (PARP) cleavage in apoptosis,” Journal of Biological Chemistry, vol. 274, no. 33, pp. 22932–22940, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Sinibaldi, W. Wharton, J. Turkson, T. Bowman, W. J. Pledger, and R. Jove, “Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling,” Oncogene, vol. 19, no. 48, pp. 5419–5427, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Gritsko, A. Williams, J. Turkson et al., “Persistent activation of STAT3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells,” Clinical Cancer Research, vol. 12, no. 1, pp. 11–19, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Xiong, Z.-G. Zhang, X.-Q. Tian et al., “Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells,” Neoplasia, vol. 10, no. 3, pp. 287–297, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Jing and D. J. Tweardy, “Targeting STAT3 in cancer therapy,” Anti-Cancer Drugs, vol. 16, no. 6, pp. 601–607, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. R. J. Leeman, V. W. Y. Lui, and J. R. Grandis, “STAT3 as a therapeutic target in head and neck cancer,” Expert Opinion on Biological Therapy, vol. 6, no. 3, pp. 231–241, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Li, S. I. Grivennikov, and M. Karin, “The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment,” Cancer Cell, vol. 19, no. 4, pp. 429–431, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Bollrath and F. R. Greten, “IKK/NF-κB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis,” EMBO Reports, vol. 10, no. 12, pp. 1314–1319, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Pensa, C. J. Watson, and V. Poli, “STAT3 and the inflammation/acute phase response in involution and breast cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 14, no. 2, pp. 121–129, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Zhou, J. Wulfkuhle, H. Zhang et al., “Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance,” Proceedings of the National Academy of Sciences, vol. 104, no. 41, pp. 16158–16163, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Behera, V. Kumar, K. Lohite, S. Karnik, and G. C. Kundu, “Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells,” Carcinogenesis, vol. 31, no. 2, pp. 192–200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Garcia, T. L. Bowman, G. Niu et al., “Constitutive activation of STAT3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells,” Oncogene, vol. 20, no. 20, pp. 2499–2513, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Watson and W. Miller, “Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts,” British Journal of Cancer, vol. 71, no. 4, pp. 840–844, 1995. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Garcia, C. L. Yu, A. Hudnall et al., “Constitutive activation of STAT3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells,” Cell Growth & Differentiation: The Molecular Biology Journal of the American Association for Cancer Research, vol. 8, no. 12, pp. 1267–1276, 1997. View at Google Scholar
  52. C. J. Ormandy, E. A. Musgrove, R. Hui, R. J. Daly, and R. L. Sutherland, “Cyclin D1, EMS1 and 11q13 amplification in breast cancer,” Breast Cancer Research and Treatment, vol. 78, no. 3, pp. 323–335, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. K. Tanaka, S. Iwamoto, G. Gon, T. Nohara, M. Iwamoto, and N. Tanigawa, “Expression of survivin and its relationship to loss of apoptosis in breast carcinomas,” Clinical Cancer Research, vol. 6, no. 1, pp. 127–134, 2000. View at Google Scholar
  54. S. M. Kennedy, L. O’Driscoll, R. Purcell et al., “Prognostic importance of survivin in breast cancer,” British Journal of Cancer, vol. 88, no. 7, pp. 1077–1083, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. N. Diaz, S. Minton, C. Cox et al., “Activation of STAT3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression,” Clinical Cancer Research, vol. 12, no. 1, pp. 20–28, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. H. Xin, C. Zhang, A. Herrmann, Y. Du, R. Figlin, and H. Yu, “Sunitinib inhibition of STAT3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells,” Cancer Research, vol. 69, no. 6, pp. 2506–2513, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. J. Choi, H. S. Kim, S. H. Park et al., “Phase II study of dovitinib in patients with castration-resistant prostate cancer (KCSG-GU11-05),” Cancer Research and Treatment, vol. 50, no. 4, pp. 1252–1259, 2018. View at Publisher · View at Google Scholar · View at Scopus
  58. J. D. Rabinowitz and E. White, “Autophagy and metabolism,” Science, vol. 330, no. 6009, pp. 1344–1348, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. A. L. Anding and E. H. Baehrecke, “Autophagy in cell life and cell death,” Current Topics in Developmental Biology, vol. 114, pp. 67–91, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Kondo and S. Kondo, “Autophagy and cancer therapy,” Autophagy, vol. 2, no. 2, pp. 85–90, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. Z. J. Yang, C. E. Chee, S. Huang, and F. A. Sinicrope, “The role of autophagy in cancer: therapeutic implications,” Molecular Cancer Therapeutics, vol. 10, no. 9, pp. 1533–1541, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Kondo, T. Kanzawa, R. Sawaya, and S. Kondo, “The role of autophagy in cancer development and response to therapy,” Nature Reviews Cancer, vol. 5, no. 9, pp. 726–734, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. W. Bursch, A. Ellinger, H. Kienzl et al., “Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy,” Carcinogenesis, vol. 17, no. 8, pp. 1595–1607, 1996. View at Publisher · View at Google Scholar · View at Scopus
  64. T. Kanzawa, I. M. Germano, T. Komata, H. Ito, Y. Kondo, and S. Kondo, “Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells,” Cell Death & Differentiation, vol. 11, no. 4, pp. 448–457, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Paglin, T. Hollister, T. Delohery et al., “A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles,” Cancer Research, vol. 61, no. 2, pp. 439–444, 2001. View at Google Scholar
  66. T. Kanzawa, Y. Kondo, H. Ito, S. Kondo, and I. Germano, “Induction of autophagic cell death in malignant glioma cells by arsenic trioxide,” Cancer Research, vol. 63, no. 9, pp. 2103–2108, 2003. View at Google Scholar
  67. A. Vazquez-Martin, C. Oliveras-Ferraros, and J. A. Menendez, “Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab,” PLoS One, vol. 4, no. 7, Article ID e6251, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. Y. Shao, Z. Gao, P. A. Marks, and X. Jiang, “Apoptotic and autophagic cell death induced by histone deacetylase inhibitors,” Proceedings of the National Academy of Sciences, vol. 101, no. 52, pp. 18030–18035, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. B. H. Huang, M. Laban, C. H.-W. Leung et al., “Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1,” Cell Death & Differentiation, vol. 12, no. 4, pp. 395–404, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Song, J. H. Noh, J. H. Lee et al., “Increased expression of histone deacetylase 2 is found in human gastric cancer,” APMIS, vol. 113, no. 4, pp. 264–268, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. J.-H. Choi, H. J. Kwon, B.-I. Yoon et al., “Expression profile of histone deacetylase 1 in gastric cancer tissues,” Japanese Journal of Cancer Research, vol. 92, no. 12, pp. 1300–1304, 2001. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Ropero and M. Esteller, “The role of histone deacetylases (HDACs) in human cancer,” Molecular Oncology, vol. 1, no. 1, pp. 19–25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. N. E. Brown, R. Jeselsohn, T. Bihani et al., “Cyclin D1 activity regulates autophagy and senescence in the mammary epithelium,” Cancer Research, vol. 72, no. 24, pp. 6477–6489, 2012. View at Publisher · View at Google Scholar · View at Scopus